Clinical Trial Update: Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America [Phase 3]

View source ↗

Summary

Phase 3 trial of a novel tetravalent dengue vaccine in children and adolescents completed; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dengue Fever
• Dengue Hemorrhagic Fever

Drugs mentioned

• novel tetravalent dengue vaccine

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Dengue Fever, Dengue Hemorrhagic Fever | Phase 3 | Status: COMPLETED | Results posted: 2019-03-27